AAPL319.97-8.24 (-2.51%) ▼|ABBV256.46-3.75 (-1.44%) ▼|ABT107.40-0.91 (-0.84%) ▼|ACN180.14-6.56 (-3.51%) ▼|ADBE259.44-7.07 (-2.65%) ▼|AMAT469.15+14.44 (+3.18%) ▲|AMD491.64+14.07 (+2.95%) ▲|AMGN403.23-34.00 (-7.78%) ▼|AMT175.47-0.28 (-0.16%) ▼|AMZN255.62-2.90 (-1.12%) ▼|AVGO366.80+8.91 (+2.49%) ▲|AXP322.83-3.26 (-1.00%) ▼|BA211.71-0.52 (-0.24%) ▼|BAC62.36-0.33 (-0.52%) ▼|BKNG187.95-5.34 (-2.76%) ▼|BLK1,107.63-8.47 (-0.76%) ▼|BMY64.75-2.09 (-3.12%) ▼|BNY163.27-1.58 (-0.96%) ▼|BRK-B501.63-4.27 (-0.84%) ▼|C136.21-1.53 (-1.11%) ▼|CAT820.33+6.47 (+0.80%) ▲|CL88.13-0.63 (-0.71%) ▼|CMCSA26.23-0.27 (-1.00%) ▼|COF216.53-3.02 (-1.38%) ▼|COP136.05+1.76 (+1.31%) ▲|COST911.37-4.38 (-0.48%) ▼|CRM251.78-7.52 (-2.90%) ▼|CSCO109.01-0.19 (-0.17%) ▼|CVS95.50-1.25 (-1.29%) ▼|CVX211.96+3.43 (+1.64%) ▲|DE687.04-6.64 (-0.96%) ▼|DHR205.38-2.24 (-1.08%) ▼|DIS104.81-0.48 (-0.46%) ▼|DUK120.54+0.32 (+0.26%) ▲|EMR152.72-0.08 (-0.05%) ▼|FDX320.49-1.88 (-0.58%) ▼|GD359.99+0.60 (+0.17%) ▲|GE335.79-1.24 (-0.37%) ▼|GEV947.49+5.57 (+0.59%) ▲|GILD146.58-4.42 (-2.92%) ▼|GM87.23-0.51 (-0.58%) ▼|GOOG332.40-2.92 (-0.87%) ▼|GOOGL335.77-2.69 (-0.79%) ▼|GS1,033.62-4.68 (-0.45%) ▼|HD320.32-0.68 (-0.21%) ▼|HON208.32-1.29 (-0.62%) ▼|IBM231.56-3.28 (-1.40%) ▼|INTC101.68+5.88 (+6.14%) ▲|INTU321.32-11.38 (-3.42%) ▼|ISRG358.51-8.19 (-2.23%) ▼|JNJ268.32-6.83 (-2.48%) ▼|JPM357.00-1.62 (-0.45%) ▼|KO88.24+0.17 (+0.19%) ▲|LIN472.33-5.25 (-1.10%) ▼|LLY1,116.00-32.74 (-2.85%) ▼|LMT536.40+11.24 (+2.14%) ▲|LOW204.33-0.24 (-0.12%) ▼|LRCX316.43+8.78 (+2.85%) ▲|MA570.32-8.85 (-1.53%) ▼|MCD255.15-0.57 (-0.22%) ▼|MDLZ61.37+0.09 (+0.15%) ▲|MDT92.35-1.81 (-1.92%) ▼|META617.88+1.11 (+0.18%) ▲|MMM168.03-0.48 (-0.28%) ▼|MO68.94+0.07 (+0.10%) ▲|MRK146.57-3.76 (-2.50%) ▼|MS217.40-0.31 (-0.14%) ▼|MSFT494.03-5.67 (-1.13%) ▼|MU1,016.88+0.29 (+0.03%) ▲|NEE83.64+0.22 (+0.26%) ▲|NFLX76.53-1.73 (-2.20%) ▼|NKE38.47+0.06 (+0.14%) ▲|NOW135.36-5.91 (-4.18%) ▼|NVDA232.54+2.18 (+0.95%) ▲|ORCL169.32+10.49 (+6.60%) ▲|PEP138.17+0.54 (+0.39%) ▲|PFE27.80-0.65 (-2.27%) ▼|PG145.43-1.02 (-0.70%) ▼|PLTR174.60+0.27 (+0.15%) ▲|PM185.36+2.85 (+1.56%) ▲|QCOM179.87+11.13 (+6.59%) ▲|RTX199.98-0.81 (-0.40%) ▼|SBUX103.69-0.79 (-0.75%) ▼|SCHW109.24-0.05 (-0.05%) ▼|SO88.49+0.37 (+0.42%) ▲|SPG208.40-0.92 (-0.44%) ▼|T25.73+0.06 (+0.23%) ▲|TMO606.80-6.95 (-1.13%) ▼|TMUS182.45+0.93 (+0.51%) ▲|TSLA361.55+7.47 (+2.11%) ▲|TXN259.58+1.14 (+0.44%) ▲|UBER73.67-2.11 (-2.78%) ▼|UNH394.29-2.81 (-0.71%) ▼|UNP288.87-0.75 (-0.26%) ▼|UPS101.61-0.68 (-0.66%) ▼|USB62.97-0.40 (-0.62%) ▼|V371.17-3.81 (-1.01%) ▼|VZ50.32+0.19 (+0.37%) ▲|WFC89.02-0.92 (-1.02%) ▼|WMT106.22-0.92 (-0.86%) ▼|XOM162.07+2.61 (+1.64%) ▲|AAPL319.97-8.24 (-2.51%) ▼|ABBV256.46-3.75 (-1.44%) ▼|ABT107.40-0.91 (-0.84%) ▼|ACN180.14-6.56 (-3.51%) ▼|ADBE259.44-7.07 (-2.65%) ▼|AMAT469.15+14.44 (+3.18%) ▲|AMD491.64+14.07 (+2.95%) ▲|AMGN403.23-34.00 (-7.78%) ▼|AMT175.47-0.28 (-0.16%) ▼|AMZN255.62-2.90 (-1.12%) ▼|AVGO366.80+8.91 (+2.49%) ▲|AXP322.83-3.26 (-1.00%) ▼|BA211.71-0.52 (-0.24%) ▼|BAC62.36-0.33 (-0.52%) ▼|BKNG187.95-5.34 (-2.76%) ▼|BLK1,107.63-8.47 (-0.76%) ▼|BMY64.75-2.09 (-3.12%) ▼|BNY163.27-1.58 (-0.96%) ▼|BRK-B501.63-4.27 (-0.84%) ▼|C136.21-1.53 (-1.11%) ▼|CAT820.33+6.47 (+0.80%) ▲|CL88.13-0.63 (-0.71%) ▼|CMCSA26.23-0.27 (-1.00%) ▼|COF216.53-3.02 (-1.38%) ▼|COP136.05+1.76 (+1.31%) ▲|COST911.37-4.38 (-0.48%) ▼|CRM251.78-7.52 (-2.90%) ▼|CSCO109.01-0.19 (-0.17%) ▼|CVS95.50-1.25 (-1.29%) ▼|CVX211.96+3.43 (+1.64%) ▲|DE687.04-6.64 (-0.96%) ▼|DHR205.38-2.24 (-1.08%) ▼|DIS104.81-0.48 (-0.46%) ▼|DUK120.54+0.32 (+0.26%) ▲|EMR152.72-0.08 (-0.05%) ▼|FDX320.49-1.88 (-0.58%) ▼|GD359.99+0.60 (+0.17%) ▲|GE335.79-1.24 (-0.37%) ▼|GEV947.49+5.57 (+0.59%) ▲|GILD146.58-4.42 (-2.92%) ▼|GM87.23-0.51 (-0.58%) ▼|GOOG332.40-2.92 (-0.87%) ▼|GOOGL335.77-2.69 (-0.79%) ▼|GS1,033.62-4.68 (-0.45%) ▼|HD320.32-0.68 (-0.21%) ▼|HON208.32-1.29 (-0.62%) ▼|IBM231.56-3.28 (-1.40%) ▼|INTC101.68+5.88 (+6.14%) ▲|INTU321.32-11.38 (-3.42%) ▼|ISRG358.51-8.19 (-2.23%) ▼|JNJ268.32-6.83 (-2.48%) ▼|JPM357.00-1.62 (-0.45%) ▼|KO88.24+0.17 (+0.19%) ▲|LIN472.33-5.25 (-1.10%) ▼|LLY1,116.00-32.74 (-2.85%) ▼|LMT536.40+11.24 (+2.14%) ▲|LOW204.33-0.24 (-0.12%) ▼|LRCX316.43+8.78 (+2.85%) ▲|MA570.32-8.85 (-1.53%) ▼|MCD255.15-0.57 (-0.22%) ▼|MDLZ61.37+0.09 (+0.15%) ▲|MDT92.35-1.81 (-1.92%) ▼|META617.88+1.11 (+0.18%) ▲|MMM168.03-0.48 (-0.28%) ▼|MO68.94+0.07 (+0.10%) ▲|MRK146.57-3.76 (-2.50%) ▼|MS217.40-0.31 (-0.14%) ▼|MSFT494.03-5.67 (-1.13%) ▼|MU1,016.88+0.29 (+0.03%) ▲|NEE83.64+0.22 (+0.26%) ▲|NFLX76.53-1.73 (-2.20%) ▼|NKE38.47+0.06 (+0.14%) ▲|NOW135.36-5.91 (-4.18%) ▼|NVDA232.54+2.18 (+0.95%) ▲|ORCL169.32+10.49 (+6.60%) ▲|PEP138.17+0.54 (+0.39%) ▲|PFE27.80-0.65 (-2.27%) ▼|PG145.43-1.02 (-0.70%) ▼|PLTR174.60+0.27 (+0.15%) ▲|PM185.36+2.85 (+1.56%) ▲|QCOM179.87+11.13 (+6.59%) ▲|RTX199.98-0.81 (-0.40%) ▼|SBUX103.69-0.79 (-0.75%) ▼|SCHW109.24-0.05 (-0.05%) ▼|SO88.49+0.37 (+0.42%) ▲|SPG208.40-0.92 (-0.44%) ▼|T25.73+0.06 (+0.23%) ▲|TMO606.80-6.95 (-1.13%) ▼|TMUS182.45+0.93 (+0.51%) ▲|TSLA361.55+7.47 (+2.11%) ▲|TXN259.58+1.14 (+0.44%) ▲|UBER73.67-2.11 (-2.78%) ▼|UNH394.29-2.81 (-0.71%) ▼|UNP288.87-0.75 (-0.26%) ▼|UPS101.61-0.68 (-0.66%) ▼|USB62.97-0.40 (-0.62%) ▼|V371.17-3.81 (-1.01%) ▼|VZ50.32+0.19 (+0.37%) ▲|WFC89.02-0.92 (-1.02%) ▼|WMT106.22-0.92 (-0.86%) ▼|XOM162.07+2.61 (+1.64%) ▲|
20 C
New York
Tuesday, September 8, 2026

Tag: evidence

newssourceFORcompanyinformationcontent1releasesmarket

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

BEERSE, BELGIUM, June 13, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced results from the investigational Phase 3 MonumenTAL-3 study.1 The results showed that TALVEY® (talquetamab), a GPRC5D bispecific antibody, in combination with daratumumab with or without pomalidomide demonstrated significant reduction in the risk of disease progression or death of up to 72.0%, and clinically meaningful reduction of up to 53.0% in the risk of death, compared to the standard regimen of daratumumab, pomalidomide, and dexamethasone (DPd) in patients with relapsed or refractory multiple myeloma (RRMM).1 Results showed a progression-free survival (PFS) rate of up to 81.3% versus standard of care (51.2%) and an overall survival (OS) rate of up to 89.2% versus standard of care (79.1%) at 24 months.1  

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

TALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 monthsMonumenTAL-3 is the...

HorseWood Claims Evaluated: The Horse Gelatin Trick for Natural Male Enhancement Support

Horsewood supplement evaluated: 7-herb botanical male vitality formula, NCCIH research context, and 60-day money-back guarantee.

Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

FDA approves Sanofi's Tzield as first disease-modifying therapy for children 8-17 with stage 3 type 1 diabetes, delaying insulin decline based on PROTECT

Avicanna Announces Closing of Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS

PreludeDx™ Achieves New Milestones for DCIS Patients and DCISionRT® Testing

LAGUNA HILLS, Calif., June 12, 2026 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in precision diagnostics for breast cancer, today highlighted a new milestone...

Allegheny Health Network’s Biomarker Moonshot Cancer Research Program Marks Five-Year Milestone, Enrolling More Than 11,000 Patients Across All Cancer Types

Systemwide research initiative uses blood‑based genomics to improve early detection and personalize cancer treatmentPITTSBURGH, June 12, 2026 /PRNewswire/ -- Allegheny Health Network (AHN) Cancer...

Pharma Equity Group prevails in international arbitration proceedings and is awarded EUR 10.5 million excluding interest and costs

About Pharma Equity Group A/S

Folger Shakespeare Library Announces Aaron T. Pratt as Andrew W. Mellon Curator of Rare Books and Prints

WASHINGTON, June 12, 2026 /PRNewswire/ -- The Folger Shakespeare Library has announced that Aaron T. Pratt will join the Collections and Exhibitions Department as...

S&P Global Energy Launches United Nations Global Compact Screening Dataset

New Sustainable1 dataset flags corporate conduct assessed against UNGC principlesLONDON and NEW YORK, June 12, 2026 /PRNewswire/ -- S&P Global Energy, the leading independent provider...

MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism

Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail™ trial

Maritime Silk Road documentary wins silver Telly Award

HAIKOU, China, June 12, 2026 /PRNewswire/ -- A news report from chinadaily.com.cn The Chinese documentary Silk Road Sunken Treasures won the Silver Award in the General Documentary...

NEDHSA Celebrates Ribbon-Cutting of R.I.S.E. Treatment Center to Address Maternal Mortality and Substance Use Disorders

MONROE, La., June 11, 2026 /PRNewswire/ -- Northeast Delta Human Services Authority (NEDHSA) officially dedicated the Reaching Independence through Support & Education (R.I.S.E.) Treatment...

ChronicleBio Is Coming for Chronic Disease: Pioneering Immunologist Joins Elite Scientific Team to Translate Biological Signal into Targeted Therapeutics

The Emerging Techbio Company Appoints Dr. John Mumm as CSO Alongside Head of Platform Dr. Yambazi Banda to Decode the Molecular Underpinnings of Neuroimmune...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsEvidence

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers